Comparative assessment of angiotensin ii type 1 receptor blockers in the treatment of acute myocardial infarction: Surmountable vs. insurmountable antagonist

International Journal of Cardiology

Volumn 170, Issue 3, 2014, Pages 291-297

  Jeong, Hae Chang ^a   Jeong, Myung Ho ^a   Ahn, Youngkeun ^a   Chae, Shung Chull ^b   Hur, Seung Ho ^c   Hong, Taek Jong ^d   Kim, Young Jo ^e   Seong, In Whan ^f   Chae, Jei Keon ^g   Rhew, Jay Young ^h   Chae, In Ho ⁱ   Cho, Myeong Chan ^g   Bae, Jang Ho ^j   Rha, Seung Woon ^k   Kim, Chong Jin ^l   Choi, Donghoon ^m   Jang, Yang Soo ^m   Yoon, Junghan ⁿ   Chung, Wook Sung ^o   Cho, Jeong Gwan ^a   Seung, Ki Bae ^o   Park, Seung Jung ^p   more..

^a Chonnam National University Medical School   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

^c Dongsan Medical Center   (South Korea)

^d Pusan National University School of Medicine   (South Korea)

^e Young Nam University Hospital   (South Korea)

^f Chungnam National University College of Medicine   (South Korea)

^g Chungbuk National University Hospital   (South Korea)

^h Jeonju Presbyterian Medical Center   (South Korea)

ⁱ Seoul National University Bundang Hospital   (South Korea)

^j Konyang University   (South Korea)

^k Korea University College of Medicine   (South Korea)

^l Kyung Hee University College of Medicine   (South Korea)

^m Yonsei University   (South Korea)

ⁿ Wonju Severance Christian Hospital   (South Korea)

^o The Catholic University of Korea   (South Korea)

^p Asan Medical Center   (South Korea)

more..

Author keywords

Angiotensin; Myocardial infarction; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CLOPIDOGREL; EPROSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; STATIN (PROTEIN); TELMISARTAN; VALSARTAN;

ACUTE HEART INFARCTION; ADVERSE OUTCOME; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPENSITY SCORE; RETREATMENT; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ANGIOTENSIN; MYOCARDIAL INFARCTION; PROGNOSIS;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CORONARY ARTERY BYPASS; CORONARY RESTENOSIS; DEATH, SUDDEN, CARDIAC; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; TREATMENT OUTCOME;

EID: 84891019906     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.07.146     Document Type: Article

References (30)

1. D.H. Elder, L. Wei, and B.R. Szwejkowski et al. The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study J Am Coll Cardiol 58 2011 2084 2091
2. S. Miyazaki, T. Kasai, and K. Miyauchi et al. Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both Circ J 74 2010 1158 1164
3. H.C. Jeong, J.M. Jeong, and M.H. Jeong et al. Effect of single or dual blockade of renin-angiotensin system in acute myocardial infarction patients according to renal function Int J Cardiol 157 2012 408 411
4. N. Shariff, C. Dunbar, and M.E. Matsumura Relation of pre-event use of inhibitors of the renin-angiotensin system with myocardial infarct size in patients presenting with a first ST-segment elevation myocardial infarction Am J Cardiol 106 2010 646 649
5. L.J. Wagenaar, A.A. Voors, and H. Buikema et al. Functional antagonism of different angiotensin II type I receptor blockers in human arteries Cardiovasc Drugs Ther 16 2002 311 316
6. G. Vauquelin, F. Fierens, and I. Van Liefde Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans J Hypertens Suppl 24 2006 S23 S30
7. Y. Cho, H.M. Yang, and K.W. Park et al. Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction: with analyses for diabetic and nondiabetic subpopulation JACC Cardiovasc Interv 3 2010 498 506
8. A. Kastrati, A. Schomig, and S. Elezi et al. Prognostic value of the modified American College of Cardiology/American Heart Association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement Circulation 100 1999 1285 1290
9. A. Manginas, P. Gatzov, C. Chasikidis, V. Voudris, G. Pavlides, and D.V. Cokkinos Estimation of coronary flow reserve using the Thrombolysis In Myocardial Infarction (TIMI) frame count method Am J Cardiol 83 1999 1562 1565 [A7]
10. R.B. D'Agostino Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 1998 2265 2281
11. T. Unger Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different? Am J Cardiol 84 1999 9S 15S
12. T. Tsutamoto, K. Nishiyama, and M. Yamaji et al. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension Hypertens Res 33 2010 118 122
13. M.T. Le, M.K. Pugsley, G. Vauquelin, and I. Van Liefde Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor Br J Pharmacol 151 2007 952 962
14. D. Lyons, S.H. Jackson, and C.G. Swift Selective AT1 receptor antagonism enhances sympathetically mediated vasoconstriction in man Clin Pharmacol Ther 81 2007 83 87
15. P. Meredith Comparative ARB, pharmacology Br J Cardiol 17 2010 s3 s5
16. M. Burnier Angiotensin II, type 1 receptor blockers Circulation 103 2001 904 912
17. A.H. Gradman AT(1)-receptor blockers: differences that matter J Hum Hypertens 16 Suppl. 3 2002 S9 S16
18. I. Van Liefde, and G. Vauquelin Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism Mol Cell Endocrinol 302 2009 237 243
19. D. Elmfeldt, B. Olofsson, and P. Meredith The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy Blood Press 11 2002 293 301
20. P.A. Meredith, L.S. Murray, and G.T. McInnes Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension J Hum Hypertens 24 2010 525 531
21. D.S. Wald, M. Law, J.K. Morris, J.P. Bestwick, and N.J. Wald Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials Am J Med 122 2009 290 300
22. S.E. Kjeldsen, J. Stalhammar, P. Hasvold, J. Bodegard, U. Olsson, and D. Russell Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension J Hum Hypertens 24 2010 263 273
23. P.A. Meredith, and S.C. Jarvis Comments on systematic review of clinical- and cost-effectiveness of candesartan and losartan in hypertension and heart failure Int J Clin Pract 65 2011 911 912
24. M. Eklind-Cervenka, L. Benson, U. Dahlstrom, M. Edner, M. Rosenqvist, and L.H. Lund Association of candesartan vs losartan with all-cause mortality in patients with heart failure JAMA 305 2011 175 182
25. M.M. Al Khalaf, L. Thalib, and S.A. Doi Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis Am J Cardiovasc Drugs 9 2009 29 43
26. A.M. Grosso, P.N. Bodalia, R.J. Macallister, A.D. Hingorani, J.C. Moon, and M.A. Scott Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis Int J Clin Pract 65 2011 253 263
27. H. Svanstrom, B. Pasternak, and A. Hviid Association of treatment with losartan vs candesartan and mortality among patients with heart failure JAMA 307 2012 1506 1512
28. J.A. Usher-Smith, T. Ramsbottom, H. Pearmain, and M. Kirby Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting Int J Clin Pract 61 2007 15 23
29. M.H. Strauss, and A.S. Hall Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox Circulation 114 2006 838 854
30. M.R. Goldstein, L. Mascitelli, and F. Pezzetta Angiotensin-receptor blockade, cancer, and concerns Lancet Oncol 11 2010 817 818